Monday, December 21, 2015

Penny Stock SNGX - Soligenix Inc.

December 17, 2015
SNGX - Soligenix Inc.
See Below Why We Like SNGX

Corporate Profile

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.


Soligenix is developing SGX301 as a first-in-class photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201), and its novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.
1.) Positive Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients, announced yesterday

2.) Further research shows us that they have a strong pipeline including a phase 3 trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma which they initiated on the 14th of this month

3.) Yesterday SNGX gapped and ran and continued to run into the close, showing a strong chance of continuing momentum.

4.) SNGX has plenty of volume for those of you who work with larger portfolios
5.) SNGX is a fully reporting OTCQB - You can view real time Level 2 on